News

ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the C9ORF72 gene that involves hundreds of additional repetitions of a six base

Promacta can now be used in combination with standard immunosuppressive therapy to treat the rare blood disorder. SAA is a condition in which the bone marrow of the

CX-01 is an investigational agent that has the potential to enhance the effectiveness of leukemia treatments by disrupting the adhesion of leukemia cells in the protective bone marrow

The companies have announced a development strategy for M710, a proposed biosimilar to Eylea injection. Eylea is a vascular endothelial growth factor (VEGF) inhibitor developed to treat neovascular

Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets. Viamet Pharmaceuticals

The job cuts will affect employees engaged in the company's commercial and other functions. Allergan said in a US Securities and Exchange Commission filing that it will also terminate nearly 400 open

CNTX-4975 is a non-opioid therapy, which is designed to inject directly into the painful joint. The company has secured funding in the series D financing round led by New

With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. PEAR is the

The consideration is INR 2,800 million (SEK 351 million1) on a cash and debt free basis whereof INR 600 million (SEK 75 million1) will be paid in newly